LNTH Q4 2025 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$6B

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$407M+4.0% YoY

Gross Profit

$241M59.2% margin

Operating Income

$77M19.0% margin

Net Income

$54M13.3% margin

EPS (Diluted)

$0.82

QoQ Revenue Growth

+5.9%

Cash Flow

Operating Cash Flow

$90M

Free Cash Flow

$81M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.1B

Stockholders' Equity

$1.1B

Cash & Equivalents

$359M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$407M	$391M	+4.0%
Gross Profit	$241M	$249M	-3.1%
Operating Income	$77M	$114M	-32.2%
Net Income	$54M	-$12M	+558.8%

Revenue Segments

Product

$389M33%

Radiopharmaceutical Oncology

$240M21%

PYLARIFY

$240M21%

Total Precision Diagnostics

$143M12%

DEFINITY

$85M7%

Strategic Partnerships And Other

$23M2%

Techne Lite

$21M2%

License and Royalty Revenues

$17M1%

Other Precision Diagnostics

$6M1%